CorMedix (CRMD) Competitors $10.74 -0.33 (-2.98%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRMD vs. AQST, NATR, CHMA, SLDB, BDTX, AMRX, SRRK, ZLAB, JANX, and CPRXShould you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Aquestive Therapeutics (AQST), Nature's Sunshine Products (NATR), Chiasma (CHMA), Solid Biosciences (SLDB), Black Diamond Therapeutics (BDTX), Amneal Pharmaceuticals (AMRX), Scholar Rock (SRRK), Zai Lab (ZLAB), Janux Therapeutics (JANX), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "medical" sector. CorMedix vs. Aquestive Therapeutics Nature's Sunshine Products Chiasma Solid Biosciences Black Diamond Therapeutics Amneal Pharmaceuticals Scholar Rock Zai Lab Janux Therapeutics Catalyst Pharmaceuticals CorMedix (NASDAQ:CRMD) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, community ranking, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Does the MarketBeat Community favor CRMD or AQST? Aquestive Therapeutics received 188 more outperform votes than CorMedix when rated by MarketBeat users. However, 73.33% of users gave CorMedix an outperform vote while only 67.96% of users gave Aquestive Therapeutics an outperform vote. CompanyUnderperformOutperformCorMedixOutperform Votes2273.33% Underperform Votes826.67% Aquestive TherapeuticsOutperform Votes21067.96% Underperform Votes9932.04% Do insiders & institutionals have more ownership in CRMD or AQST? 34.2% of CorMedix shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 5.2% of CorMedix shares are held by company insiders. Comparatively, 7.9% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer CRMD or AQST? CorMedix presently has a consensus target price of $15.20, indicating a potential upside of 41.53%. Aquestive Therapeutics has a consensus target price of $9.80, indicating a potential upside of 106.97%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Aquestive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Is CRMD or AQST more profitable? CorMedix has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -59.75%. Aquestive Therapeutics' return on equity of 0.00% beat CorMedix's return on equity.Company Net Margins Return on Equity Return on Assets CorMedixN/A -79.21% -64.68% Aquestive Therapeutics -59.75%N/A -33.96% Does the media favor CRMD or AQST? In the previous week, Aquestive Therapeutics had 1 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 3 mentions for CorMedix. Aquestive Therapeutics' average media sentiment score of 1.49 beat CorMedix's score of 0.45 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aquestive Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CRMD or AQST? CorMedix has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Aquestive Therapeutics has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Which has higher valuation and earnings, CRMD or AQST? Aquestive Therapeutics has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$60K10,861.72-$46.34M-$0.81-13.26Aquestive Therapeutics$50.58M8.54-$7.87M-$0.45-10.52 SummaryAquestive Therapeutics beats CorMedix on 14 of the 18 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRMD vs. The Competition Export to ExcelMetricCorMedixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$671.70M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-13.264.8587.8613.46Price / Sales10,861.72374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book11.0710.216.946.30Net Income-$46.34M$153.61M$119.12M$225.93M7 Day Performance-2.36%-2.00%-1.84%-1.32%1 Month Performance-4.11%-7.47%-3.65%0.60%1 Year Performance196.69%31.80%31.64%26.23% CorMedix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRMDCorMedix2.6748 of 5 stars$10.74-3.0%$15.20+41.5%+184.1%$671.70M$60,000.00-13.2630Insider TradeAQSTAquestive Therapeutics2.266 of 5 stars$4.74-1.7%$9.80+107.0%+164.5%$439.48M$50.58M-10.52160Short Interest ↓Positive NewsNATRNature's Sunshine Products2.7973 of 5 stars$16.00+0.2%$19.00+18.8%-7.5%$295.05M$445.32M18.18814Positive NewsCHMAChiasmaN/A$3.76flatN/A+0.0%$217.68M$1.11M-2.6385Analyst ForecastSLDBSolid Biosciences3.3235 of 5 stars$4.96-2.9%$15.14+205.3%+108.4%$204.17M$8.09M-1.63100Analyst RevisionBDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.43-4.7%$15.50+537.9%+8.0%$144.29MN/A0.0090Positive NewsAMRXAmneal Pharmaceuticals3.211 of 5 stars$8.41-0.4%$10.00+18.9%+86.9%$2.61B$2.39B0.007,700Insider TradeSRRKScholar Rock4.185 of 5 stars$27.86flat$34.00+22.0%+137.1%$2.61B$33.19M-11.86140ZLABZai Lab2.9675 of 5 stars$26.23+0.3%$52.50+100.2%-7.2%$2.60B$266.72M-9.472,175Analyst RevisionJANXJanux Therapeutics3.5908 of 5 stars$48.96-0.1%$66.44+35.7%+441.0%$2.57B$8.08M0.0030CPRXCatalyst Pharmaceuticals4.7417 of 5 stars$21.15-1.1%$31.14+47.2%+54.3%$2.55B$398.20M17.92167Analyst Forecast Related Companies and Tools Related Companies AQST Alternatives NATR Alternatives CHMA Alternatives SLDB Alternatives BDTX Alternatives AMRX Alternatives SRRK Alternatives ZLAB Alternatives JANX Alternatives CPRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRMD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRMD Stock Alerts